<DOC>
	<DOCNO>NCT02558894</DOCNO>
	<brief_summary>A Phase II Open-Label , Multi-Center Study MEDI4736 Evaluated Single Agent Combination Tremelimumab Patients Metastatic Pancreatic Ductal Adenocarcinoma .</brief_summary>
	<brief_title>Phase II Study MEDI4736 Monotherapy Combinations With Tremelimumab Metastatic Pancreatic Ductal Carcinoma</brief_title>
	<detailed_description>This Phase II , open-label , multi-center study determine efficacy safety MEDI4736 evaluate single agent combination tremelimumab patient metastatic pancreatic ductal adenocarcinoma ( PDAC ) whose disease progress fluoropyrimidine contain gemcitabine-containing first-line chemotherapy.This study consist Part A , lead-in , well possible expansion Part B .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Histologically cytologically confirm metastatic PDAC , 1 prior chemotherapy regimen 2 . Eastern Cooperative Oncology Group 0 1 3 . At least 1 lesion , previously irradiate , accurately measure baseline ≥10 mm long diameter ( except lymph node , must short axis ≥15 mm ) compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan suitable accurate repeat measurement 1 . Any concurrent chemotherapy , investigational product , biologic , hormonal therapy cancer treatment . 2 . History leptomeningeal carcinomatosis 3 . Ascites require intervention 4 . Brain metastasis spinal cord compression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pancreatic Ductal Adenocarcinoma , PDAC</keyword>
</DOC>